
    
      This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose,
      dose-escalation, safety, PK, and PD study of ALX148. The phase 1 protocol will have 2 parts:
      a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part
      2 will include an initial dose escalation portion followed by a dose expansion portion.
      Approximately 184 adult patients are expected to be enrolled in the study.
    
  